Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL460815 | 1.00 | ALDH1A1 (0.45) | ALDH1A1NOTUMKMT2AKDM4ETSHR | |
| SCHEMBL1740735 | 0.75 | ALDH1A1 (0.55) | ALDH1A1NOTUMKMT2AKDM4ETSHR | |
| SCHEMBL28425870 | 0.69 | ALDH1A1 (0.60) | ALDH1A1NOTUMKMT2AKDM4ETSHR | |
| SCHEMBL22637403 | 0.66 | ALDH1A1 (0.56) | ALDH1A1NOTUMKMT2AKDM4ETSHR | |
| SCHEMBL430921 | 0.64 | ALDH1A1 (0.61) | ALDH1A1NOTUMKMT2AKDM4ETSHR | |
| SCHEMBL14778436 | 0.63 | ALDH1A1 (0.60) | ALDH1A1NOTUMKMT2AKDM4ETSHR | |
| SCHEMBL22636958 | 0.63 | ALDH1A1 (0.56) | ALDH1A1NOTUMKMT2AKDM4ETSHR | |
| SCHEMBL431148 | 0.63 | ALDH1A1 (0.43) | ALDH1A1NOTUMKMT2AKDM4ETSHR | |
| SCHEMBL10199133 | 0.61 | NOTUM (0.33) | ALDH1A1NOTUM | |
| SCHEMBL430561 | 0.60 | ALDH1A1 (0.43) | ALDH1A1NOTUMKMT2AKDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2595982-B1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | RIGEL PHARMACEUTICALS INC (US) | 2018-06-13 | — | — | EP | disclosed |
| US-9181222-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20140329842-A1 | Protein Kinase C Inhibitors and Uses Thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-8710223-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-20120022092-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | MIDCAP FINANCIAL TRUST | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329842-A1 | Protein Kinase C Inhibitors and Uses Thereof | PRKCH, PRKCA, PRKCB | ALDH1A1 4361/4885NOTUM 1505/4885KMT2A 3505/4885 |
| US-20120022092-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | PRKCH, PRKCA, PRKCB | ALDH1A1 4361/4885NOTUM 1505/4885KMT2A 3505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.